Zeldox (Ziprasidone)

Zeldox (ziprasidone) is an intramuscular antipsychotic injection used for acute agitation in schizophrenia. It belongs to the atypical antipsychotic class and is administered by healthcare professionals. This formulation provides rapid symptom control for patients requiring injectable therapy. Short-term use only; consult a physician for ongoing treatment plans.

Zeldox (ziprasidone) is used for short-term management of acute agitation in adults with schizophrenia. It helps calm severe symptoms such as aggression, hostility, or extreme restlessness. The intramuscular form allows quick onset of action when oral medication is not feasible. This medication is intended for use under medical supervision in clinical settings.

After intramuscular administration, effects typically appear within 15–30 minutes, with peak sedation observed around 60–90 minutes. Patients may experience drowsiness, reduced motor agitation, and calming effects. Individual responses vary, and effects are temporary, lasting several hours. Monitoring by healthcare staff ensures appropriate care during administration.

Zeldox should only be administered by trained healthcare professionals in a controlled setting. Patients with known hypersensitivity to ziprasidone should avoid this medication. Caution is advised in elderly patients or those with cardiovascular conditions due to potential sedative effects. Always disclose full medical history before receiving this injection.

Concurrent use with alcohol or central nervous system depressants may increase sedation. Ziprasidone may interact with medications affecting heart rhythm or blood pressure. CYP3A4 inhibitors can alter drug levels; consult a healthcare provider before combining therapies. Avoid abrupt discontinuation of other psychotropic medications without medical guidance.